When used for obesity, the results are even more dramaticpeople taking semaglutide, the active ingredient in Ozempic, for instance, report an average weight loss of 12.7 kg (nearly 28 pounds) over 68 weeks compared to a placebo
Lower cardiovascular risk: Studies show a 20% reduced risk of heart attack or stroke in people with obesity, and 26% in those with both obesity and diabetes
People who are overweight are at higher risk for developing a number of diseases and illnesses, including heart disease and stroke, hypertension, type 2 diabetes, some cancers, and problems with muscles and joints
Before you enroll, there are two gaps in Omzo's public materials you'll need to fill yourself
Abbott is identified as a leading player in the market, supported by its strong portfolio of advanced nutritional supplements including protein shakes, digestive health products, and glucose management solutions, continuous innovation in GLP1 companion formulations, and global presence across home consumption, clinical nutrition, and diabetes care programs.